{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:33:56Z","timestamp":1768440836945,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004343","name":"Stavros Niarchos Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.nmd.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T23:19:59Z","timestamp":1660173599000},"page":"847-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of the nicotinic acetylcholine receptor antibodies after an unexpected increase of antibody titer in thymoma associated myasthenia gravis patients"],"prefix":"10.1016","volume":"32","author":[{"given":"Vasiliki","family":"Zouvelou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Michail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Belimezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Haroniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Zisimopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.08.003_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2022.08.003_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.1017","article-title":"Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis","volume":"50","author":"Buckley","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2022.08.003_bib0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","article-title":"Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study","volume":"10","author":"Romi","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0006","first-page":"106","article-title":"Thymoma_associated myasthenia gravis: clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma","volume":"12","author":"De","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.nmd.2022.08.003_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nmd.2022.08.003_bib0008","article-title":"The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis","volume":"13","author":"Rodr\u00edguez","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.nmd.2022.08.003_bib0009","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/neu.10153","article-title":"The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences","volume":"53","author":"Le Nov\u00e8re","year":"2002","journal-title":"J Neurobiol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jmb.2004.12.031","article-title":"Refined structure of the nicotinic acetylcholine receptor at 4A resolution","volume":"346","author":"Unwin","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2022.08.003_bib0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2008.06.002","article-title":"Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients\u2019 sera using Escherichia coli-expressed receptor domains","volume":"200","author":"Zisimopoulou","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0013","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1002\/mus.27177","article-title":"Subunit specificity of the acetylcholine receptor antibodies in double seropositive myasthenia gravis","volume":"63","author":"Zouvelou","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.08.003_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.858998","article-title":"Analysis of nAChR Autoantibodies Against Extracellular Epitopes in MG Patients","volume":"13","author":"Michail","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.08.003_bib0016","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2022.08.003_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.07.018","article-title":"Extracellular domains of the \u03b2, \u03b3 and \u03b5 subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency","volume":"190","author":"Kostelidou","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.10.002","article-title":"Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor \u03b1-subunit. Development of an antigen-specific therapeutic strategy","volume":"159","author":"Psaridi-Linardaki","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2022.08.003_bib0019","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of acetylcholine receptor autoantibody\u2013mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622006319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622006319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:59Z","timestamp":1760775179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622006319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0960896622006319"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.08.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the nicotinic acetylcholine receptor antibodies after an unexpected increase of antibody titer in thymoma associated myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}